Research Article Details
Article ID: | A17349 |
PMID: | 27831641 |
Source: | Eur Rev Med Pharmacol Sci |
Title: | Metabolic syndrome is a risk factor for nonalcoholic fatty liver disease: evidence from a confirmatory factor analysis and structural equation modeling. |
Abstract: | OBJECTIVE: It has been demonstrated that nonalcoholic fatty liver disease (NAFLD) is associated with metabolic syndrome (MS). This study used confirmatory factor analysis (CFA) and structural equation modeling (SEM) to characterize the relationship between MS and NAFLD. PATIENTS AND METHODS: A cross-sectional study was performed on 3440 NAFLD patients. Of the 3440 subjects, 1160 were diagnosed with MS. BMI, SBP, DBP, UN, Scr, UA, FPG, Fructosamine, TC, TG, lipoprotein alpha, HDL-C, LDL-C, ALT, AST, TP, albumin, globulins, TB, DB, ALP and GGT were measured. CFA was used to identify a latent structure of NAFLD and MS, respectively. SEM approach was used to analyze the latent relationship between MS and NAFLD. RESULTS: Second-order CFA revealed that the observed variables for NAFLD could be loaded onto seven latent factors, which were further loaded together onto an unobserved NAFLD factor. CFA of MS showed that overweight, hyperglycemia, dyslipidemia, and hypertension clustered together under a single latent factor of MS. In both MS and NAFLD models, hypertension showed higher factor loading than other factors. Factor models of MS and NAFLD showed a good fit to the data. As a latent factor, MS was significantly associated with increased risk of NAFLD. CONCLUSIONS: MS may be a risk factor of NAFLD. MS and its components may play important roles in the development of NAFLD. |
DOI: |

Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs |
---|
Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
---|
Diseases ID | DO ID | Disease Name | Definition | Class | |
---|---|---|---|---|---|
I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
I12 | 10763 | Hypertension | An artery disease characterized by chronic elevated blood pressure in the arteries. https://en.wikipedia.org/wiki/Hypertension, https://www.ncbi.nlm.nih.gov/pubmed/24352797 | disease of anatomical entity/ cardiovascular system disease/vascular disease/ artery disease | Details |
I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
---|---|---|---|---|---|---|---|
D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |